Building a better understanding of Low-Grade ovarian cancer
NCT ID NCT00488878
First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or procedures are being tested; this is purely an information-gathering effort.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this database could help researchers identify patterns and develop better treatments for low-grade ovarian and peritoneal cancers.
- What could go wrong
- This is an observational data collection study, not a treatment trial. It does not test any new therapy, so there is no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2006
- Expected to finish
-
May 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a low-grade tumor of Mullerian origin who sought treatment or a second opinion at MD Anderson Cancer Center (MDACC) at any point in the course of their disease and treatment (beginning in January 1950), and patients currently being treated at MDACC or seeking treatment or a second opinion in the future
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis: * Ovarian tumor of low malignant potential * Low-grade serous carcinoma of the ovary * Primary peritoneal tumor of low malignant potential * Low-grade serous carcinoma of the peritoneum * Psammocarcinoma
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Low grade ovarian serous adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Triple oral drug combo targets two stubborn gynecologic cancers
- New antibody aims to preserve immune checkpoint while fighting cancer
- Blood vessel cells in a simple blood test may predict ovarian cancer therapy success
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Can new tracers make many cancers light up on scans?
- Can a Dual-Payload 'Smart Bomb' outsmart advanced ovarian cancer?